PDX model details
| PDX ID |
201.1A |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
42 |
| Average PDX Generation Time (days +/- SEM) |
35 ± 2 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304; 30049486 |
| |
|
| Markers |
201.1A |
| AR |
Y |
| PSA |
Y |
| PSMA |
N |
| NE |
N |
| ERG |
Y |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 201.1A |
CDKN1B |
-0.954155 |
1.03229 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 201.1A |
KMT2A |
0.816013 |
3.52107 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 201.1A |
MLH1 |
-0.817194 |
1.13509 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 201.1A |
PTEN |
-2.02003 |
0.493106 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 201.1A |
PTEN |
-12.2328 |
0.000415518 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 201.1A |
RB1 |
-16.8488 |
0.0000169 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 201.1A |
SUFU |
-2.02003 |
0.493106 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 201.1A |
ZFHX3 |
0.819031 |
3.52844 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
Clinical Information
| Sample Number |
201.1A |
| Sample Site |
Dura |
| Sample source |
Autopsy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
| |
|
Patient Information
| Patient Number |
201 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 201.1A |
AR |
204 |
1.0 |
missense_variant |
'8/8 |
. |
25.3 |
Pathogenic
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
AR |
945 |
0.99 |
missense_variant |
'4/8 |
. |
23.2 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
MLH1 |
142 |
0.96 |
inframe_insertion,splice_region_variant |
'10/19 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
MLH1 |
168 |
0.82 |
splice_acceptor_variant |
. |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
CACNA1H |
107 |
0.5 |
missense_variant |
'9/35 |
8.90E-05 |
5.716 |
Uncertain_significance
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
TGFBR2 |
119 |
0.5 |
frameshift_variant |
'4/8 |
0.0003621 |
35 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
CTNNB1 |
346 |
0.5 |
missense_variant |
'3/15 |
. |
29.9 |
Pathogenic/Likely_pathogenic,_other
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
MSH2 |
298 |
0.49 |
missense_variant |
'16/16 |
6.12E-05 |
27.7 |
Uncertain_significance
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
KMT2D |
1715 |
0.49 |
missense_variant |
'48/54 |
. |
33 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
GSK3B |
366 |
0.48 |
missense_variant |
'6/12 |
. |
27.4 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
GLI2 |
368 |
0.48 |
missense_variant |
'14/14 |
. |
24.3 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
SIX3 |
1013 |
0.46 |
frameshift_variant |
'1/2 |
0 |
28.8 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
MUTYH |
1218 |
0.46 |
missense_variant |
'13/16 |
0.0007924 |
20.7 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
KMT2C |
208 |
0.45 |
stop_gained |
'36/59 |
0 |
40 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
BLM |
469 |
0.45 |
frameshift_variant |
'7/22 |
2.95E-05 |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
GLI2 |
1572 |
0.44 |
missense_variant |
'4/14 |
4.06E-06 |
29.6 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
AIP |
1324 |
0.44 |
missense_variant |
'6/6 |
. |
29.7 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
BRCA2 |
222 |
0.42 |
frameshift_variant |
'11/28 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
OGDH |
139 |
0.41 |
frameshift_variant |
'22/23 |
. |
35 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
SIRT1 |
42 |
0.4 |
frameshift_variant |
'1/9 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
MSH6 |
464 |
0.4 |
frameshift_variant |
'4/10 |
. |
24.1 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
TERT |
124 |
0.39 |
missense_variant |
'2/16 |
. |
5.144 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
NFE2L1 |
580 |
0.38 |
frameshift_variant |
'2/6 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
ZFHX3 |
1418 |
0.34 |
frameshift_variant |
'2/10 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
ASXL1 |
730 |
0.34 |
frameshift_variant |
'13/13 |
0.0004861 |
34 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
BBC3 |
310 |
0.34 |
frameshift_variant |
'4/4 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 201.1A |
CTCF |
536 |
0.28 |
stop_gained |
'11/12 |
. |
39 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
No information in Drug dosing Table